Results 11 to 20 of about 512,272 (346)
Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening
Hepatology Communications, 2023 Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID‐19) pandemic.
Aaron Vanderhoff +17 more
doaj +2 more sources
PREVALENCE OF MARKERS OF VIRAL HEPATITIS B AND D FROM HEALTHY POPULATION IN REPUBLIC TYVA
Детские инфекции (Москва), 2015 Aim: to estimate prevalence of markers, genetic diversity, risk factors of HBV and HDV infections in all age groups among healthy population in Republic Tyva.
T. V. Kozhanova +8 more
doaj +1 more source
Clinical Case Reports, 2021 Nonhospitalized COVID‐19 and hepatitis C‐coinfected patient presented prolonged RNA shedding and mild course of infection. This finding demonstrated the importance of long follow‐up of these patients.
Livia Melo Villar +11 more
doaj +1 more source
The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]
, 2019 The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G +12 more
core +3 more sources
Emerging Microbes and Infections, 2022 Coronavirus disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has set off a global pandemic. There is an urgent unmet need for safe, affordable, and effective therapeutics against COVID-19.
Binli Mao +18 more
doaj +1 more source
Monitoring response to hepatitis B and C in EU/EEA: testing policies, availability of data on care cascade and chronic viral hepatitis-related mortality – results from two surveys (2016) [PDF]
, 2018 Objectives: The World Health Organization (WHO) developed a European Regional Action Plan (EAP) to fast-track action towards the goal of eliminating viral hepatitis. Robust monitoring is essential to assess national programme performance.
De Brujin +11 more
core +1 more source
Automated quality control for a molecular surveillance system
BMC Bioinformatics, 2018 Background Molecular surveillance and outbreak investigation are important for elimination of hepatitis C virus (HCV) infection in the United States. A web-based system, Global Hepatitis Outbreak and Surveillance Technology (GHOST), has been developed ...
Seth Sims +10 more
doaj +1 more source
An M0 macrophage-related prognostic model for hepatocellular carcinoma
BMC Cancer, 2022 Background The role of M0 macrophages and their related genes in the prognosis of hepatocellular carcinoma (HCC) remains poorly characterized. Methods Multidimensional bioinformatic methods were used to construct a risk score model using M0 macrophage ...
Yiya Zhang, Ju Zou, Ruochan Chen
doaj +1 more source
Brazilian Journal of Infectious Diseases, 2012 Background: Pegylated interferon (Peg-IFN) and standard interferon (IFN) play a significant role in the treatment of hepatitis C virus (HCV) infection. Biosimilar standard IFN is widely available in Brazil for the treatment of HCV infection genotypes 2 ...
Aline Gonzalez Vigani +9 more
doaj +1 more source
Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia
Substance Abuse Treatment, Prevention, and Policy, 2022 Background People who inject drugs (PWID) in Georgia have a high prevalence of hepatitis C virus antibody (anti-HCV). Access to care among PWID could be prioritized to meet the country’s hepatitis C elimination goals.
Maia Butsashvili +13 more
doaj +1 more source